Compare iShares MSCI France ETF (EWQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Smith & Nephew plc — how do they compare? iShares MSCI France ETF trades at $41.51 (market cap $330.91M), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 33.5× iShares MSCI France ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while iShares MSCI France ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI France ETF for 55 Days and Smith & Nephew plc for 121 Days on average.
| EWQ | SNN | |
|---|---|---|
Market Cap | $330.91M | $11.10B |
Volume | 556,654 | 1,051,703 |
Sector | Broad Market / Factor | Health |
52-Week High | $48.35 | $37.17 |
52-Week Low | $41.32 | $26.42 |
Typical Hold Time | 55 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWQ is currently trading at $41.34, down 1.12% on the day, with technical indicators showing a bearish trend despite oversold RSI readings. The stock faces significant technical pressure with moving averages signaling strong selling momentum. Recent news highlights European market volatility driven by ECB rate hikes and energy price inflation, creating headwinds for European-focused investments.
The outlook remains cautious as monetary tightening and geopolitical risks weigh on European equities. Key support sits at $41 with resistance at $42, while oversold conditions suggest potential for near-term stabilization. However, sustained recovery depends on easing inflation pressures and improved eurozone economic sentiment.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
